Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- (-) Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- (-) Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- (-) Real-World Data
- (-) Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- (-) Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Display Only
Showing 97 Results
Missed Signals in Cancer Care: Strategies to Address Quality Measure Gaps
When it comes to designing accountable care models, the dramatically varied needs and preferences of patients with cancer can confound quality measurement, especially when compounded by increasingly…
Improving Oncology Quality Measurement in Accountable Care: Filling Gaps with Cross-Cutting Measures
According to a study, gaps in the quality measures used by accountable care programs to assess cancer care may obscure problems in care delivery and lead to missed opportunities for improvement of…
The Central Role of Physician Leadership for Driving Change in Value-Based Care Environments
This case study analyzing accountable care organizations looks at lessons learned from the implementation of the American Medical Group Foundation’s Measure Up/Pressure Down initiative.
Data, Data Everywhere, But Access Remains a Big Issue for Researchers
This study captures the policy inconsistencies and hurdles that can hinder use of publicly funded federal and state datasets for researchers. These limitations can make it harder to conduct high…
Why Is Broader Access to Publicly Funded Data Important?
This infographic illustrates the policy inconsistencies and hurdles that can hinder use of publicly funded federal and state datasets for researchers.
Using an Electronic Medication Refill System to Improve Provider Productivity in an Accountable Care Setting
This case study highlights the critical components of Sharp Rees-Stealy Medical Group's electronic medication refill system that allows for a centralized team to manage all incoming prescription…
Solutions for Filling Gaps in Accountable Care Measure Sets
This peer-reviewed study, “Solutions for Filling Gaps in Accountable Care Measure Sets,” explores measurement gaps for high-priority conditions and identifies ways to improve measure sets.
Developing Evidence that is Fit for Purpose: A Framework for Payer and Research Dialogue
A study published in the September 2015 issue of The American Journal of Managed Care introduces a framework developed by the National Pharmaceutical Council (NPC) and AcademyHealth that could help…
Private Sector Risk-Sharing Agreements in the US: Trends, Barriers and Prospects
A peer-reviewed study found that there are limited risk-sharing agreements (RSAs) between health care payers and pharmaceutical manufacturers in the United States, but interest in the agreements…
When Does FDAMA Section 114 Apply? Ten Case Studies
There is hesitation to disseminate comparative effectiveness research because of ambiguities in the law that was established to help biopharmaceutical companies engage health plans around real-world…
Translating Comparative Effectiveness Research into Medicaid Payment Policy: Views from Medical and Pharmacy Directors
NPC supported a survey of Medicaid medical and pharmacy directors to better understand how policy makers in the state Medicaid programs view comparative effectiveness research (CER) and how they use…
Best Practices: An Electronic Drug Alert Program to Improve Safety in an Accountable Care Environment
This case study highlights the critical components of Marshfield Clinic’s Drug Safety Alert Program, which focuses on prioritizing and communicating safety issues related to medications with the goal…
Exploration of Heterogeneity in Distributed Research Network Drug Safety Analyses
Distributed data network drug safety analyses are difficult to interpret in the face of heterogeneity, or individual treatment effects.
Best Practices: Improving Patient Outcomes and Costs in an ACO Through Comprehensive Medication Therapy Management
This case study explores the important role that pharmacists can play in ensuring the optimal use of pharmaceuticals and improving patient outcomes in an accountable care organization (ACO). It …
Accountable Care Measures for High-Cost Specialty Care and Innovative Treatment
This comprehensive white paper from the National Pharmaceutical Council and Discern Health identified gaps in accountable care quality measure sets for cancer, which can lead to missed opportunities…
Consumer-Directed Health Plans: Pharmacy Benefits & "Better Practices"
The research was intended to identify the current landscape and best practice approaches for consumer-directed health plans and pharmacy benefits, as well as understand the health and economic impact…
Individual Treatment Effects: Implications for Research, Clinical Practice, and Policy
This research outlines a framework and policy considerations to help health care stakeholders understand when it is important take patients’ individual treatment responses into account when making…
Real-World Impact of Comparative Effectiveness Research Findings on Clinical Practice
This study suggests that changes are needed to enable more consistent translation of research findings into clinical practice.
Supporting Consumer Access to Specialty Medications Through Value-Based Insurance Design
Value-based insurance design (V-BID) is a key tactic payers and purchasers can use to promote access to high-value specialty medications.